Patients on direct oral anticoagulants requiring urgent interventions pose a challenge for
clinicians.
An 89-year-old man was admitted due to syncopal attacks and dyspnea at rest since few days.
The single chamber pacemaker was implanted one month before in another hospital, due to symptomatic atrial fibrillation with complete atrioventricular block. No perioperative complications were reported. Idarucizumab, a monoclonal antibody fragment is the first available targeted reversal agent specific for dabigatran that binds it with a high affinity [3] . Nevertheless, experience with the idarucizumab in patients with severe kidney failure (GFR<30 mL/min) is limited. The idarucizumab half-time is prolonged in patients with renal failure, however greater idarucizumab exposure seems to be favorable, because these patients have also elevated plasma dabigatran concentrations [4, 5] . In presented case, idarucizumab allowed to successfully neutralize dabigatran activity and enable transvenous lead explantation without excess bleeding despite coexistent severe kidney failure. 
